Important Safety Information:
CONTRAINDICATIONS: ELOCTATE is contraindicated in patients who have had life-threatening hypersensitivity reactions to ELOCTATE or its excipients.
WARNINGS AND PRECAUTIONS: Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products.Full Important Safety Information
Information in the above calculator is provided as a guide for dosing ELOCTATE for prophylaxis, the control of bleeding episodes, and perioperative management. Your independent medical consideration should be given to maintaining factor VIII activity at or above the target range.
*Minor and moderate bleed events: joint, superficial muscle/no neurovascular compromise (except iliopsoas), deep laceration and renal, superficial soft tissue, mucous membranes.1
†Major bleed events: life- or limb-threatening hemorrhage, iliopsoas and deep muscle with neurovascular injury, retroperitoneum, intracranial, or gastrointestinal.1
‡Eligibility criteria apply. Those with federal and state government insurance, such as Medicare, Medicaid, or TRICARE®, are not eligible. Have your patients contact their MyELOCTATE™ Coordinator to see if they are eligible for any of these programs. Sanofi Genzyme reserves the right to modify or discontinue these programs at any time. TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.